Vivitrol

This page contains recent news articles, when available, and an overview of Vivitrol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Alkermes books 1Q loss without Eli Lilly payment  -  ‎Aug 6, 2009‎
...drug Risperdal Consta, which is marketed by Johnson & Johnson, and receives revenue from sales of Cephalon Inc.'s alcohol dependency drug Vivitrol. Forbes

Take The First Step: Medications to help people stop drinking  -  ‎Aug 6, 2009‎
I should also mention that this medication is available in an injectable form, which is called Vivitrol. Vivitrol must be taken monthly and is given by a Eagle Tribune

Trader sees Alkermes heading up-07/07/2009  -  ‎Jul 7, 2009‎
Yesterday's options trader may be wagering on good news from a Phase III trial of the company's Vivitrol drug, which is currently approved for alcohol NASDAQ

Smaller companies win in most valuable race  -  ‎Jun 30, 2009‎
...has benefited from its proprietary drug delivery technology used in Johnson & Johnson's Risperdal Consta, and its own alcohol dependency drug, Vivitrol. Seeking Alpha

'뉴비질' 새 �?�?��? 추가 승�?�신청  -  ‎Jul 1, 2009‎
...�?� 회사는 중추신경계 치료제 분야�? 다양한 약제를 가지고 있으며 알코올 중�?� 치료용 주사제 '비비트롤'(Vivitrol/ 날트렉�? 서방형 주사제), 암 관련 통�?완화제 헬스코리아뉴스

세계 제약사 중 최고 마진�?� 69%  -  ‎Jun 22, 2009‎
...�?�는 알커메스�?� 약물전달 기술�?� �?�용한 '리스페달 콘스타'와 알코올 �?�존�? 치료제 '비비트롤'(Vivitrol, Naltrexone XR)�?� �?�분�?� 것으로 설명�??다. 디지틀보사

Alkermes shares rise on analyst upgrade  -  ‎Apr 13, 2009‎
Hazlett also does not expect a meaningful pickup from current prescription levels for the alcohol dependency drug Vivitrol. "Challenges exist for Consta, Forbes

US HOT STOCKS: Goldman Sachs, Talbots Active In Late Trading  -  ‎Apr 13, 2009‎
BMO said doubts about the drug maker's once-weekly exenatide drug to treat Type II diabetes and its alcoholism treatment, Vivitrol, appear largely priced Wall Street Journal

Biotech Industry  -  ‎Apr 17, 2009‎
For ALKS, termination of recent two deals with Eli Lilly (LLY) and Cephalon (CEPH) for the inhaled insulin program and Vivitrol, respectively, Zacks.com

Alkermes Highlights Advancing Proprietary Product Portfolio at R&D Day  -  ‎Apr 7, 2009‎
Alkermes developed, manufactures and commercializes VIVITROL ® for alcohol dependence and manufactures RISPERDAL ® CONSTA ® for schizophrenia. Business Wire (press release)

Drug Suppresses The Compulsion To Steal, Study Shows  -  ‎Apr 2, 2009‎
An extended-release formulation is sold under the name Vivitrol. The research was supported by a Career Development Award from the National Institute of Science Daily (press release)

OxyContin Addiction Treatment Evolves To Stem the Tide  -  ‎Apr 8, 2009‎
Drugs like Suboxone or Vivitrol may be used to minimize cravings in early sobriety. The program includes special process groups and educational workshops TransWorldNews (press release)

Anti-addiction pill blunts craving  -  ‎Apr 15, 2009‎
Along with therapy, virtually every patient is given Vivitrol, a long-lasting form of naltrexone that's given monthly by injection. WTHI

Adequate 3Q for Alkermes  -  ‎Mar 13, 2009‎
Also during the quarter, Alkermes regained commercial rights to alcoholism drug Vivitrol from Cephalon and will begin marketing the product itself. Morningstar.ca

Alkermes’ Corporate Presentation to be Webcast at the Cowen and ...  -  ‎Mar 10, 2009‎
Alkermes developed, manufactures and commercializes VIVITROL ® for alcohol dependence and manufactures RISPERDAL ® CONSTA ® for schizophrenia. Earthtimes (press release)

Biotech Industry  -  ‎Mar 12, 2009‎
For ALKS, the termination of two recent deals with Eli Lilly (LLY) and Cephalon (CEPH) for the inhaled insulin program and Vivitrol respectively have major Zacks.com

Alkermes Announces Initiation Of Phase 2a Clinical Study Of ALKS ...  -  ‎Feb 20, 2009‎
Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia. Medical News Today (press release)

Alkermes to Host Conference Call to Discuss Financial Results for ...  -  Jan 29, 2009
Alkermes developed, manufactures and commercializes VIVITROL ® for alcohol dependence and manufactures RISPERDAL ® CONSTA ® for schizophrenia. WELT ONLINE,

Alkermes' Corporate Presentation to be Webcast at JPMorgan Annual ...  -  Jan 12, 2009
Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia. PR-Inside.com (Pressemitteilung),

Alkermes Announces Initiation of First Clinical Study for a Four ...  -  Jan 9, 2009
Alkermes developed, manufactures and commercializes VIVITROL ® for alcohol dependence and manufactures RISPERDAL ® CONSTA ® for schizophrenia. WELT ONLINE,

Abusing alcohol  -  Jan 10, 2009
In addition, an injectable, long-acting form of naltrexone (Vivitrol®) is available. These medications have been shown to help people with dependence reduce Malaysia Star,

How to Survive the Downturn: Five Questions With Boston Biotech ...  -  Jan 15, 2009
What we like is that we have a base business that’s profitable, driven by a product called Risperdal Consta, a commercial opportunity with Vivitrol, Xconomy,

Dipendenza da alcol: Vivitrol può causare gravi reazioni al sito ...  -  Jan 19, 2009
Lunedì 19 Gennaio 2009 - L’FDA ( Food and Drug Administration ) ha approvato Vivitrol ( Naltrexone ) nell’aprile 2006, per il trattamento della dipendenza XagenaSalute,

ANALYSIS-Alkermes' Vivitrol needs opioid market to boost sales  -  Dec 22, 2008
By Vidya L Nathan BANGALORE, Dec 22 (Reuters) - As sales of Alkermes Inc's drug to treat alcohol dependence, Vivitrol, have failed to take off, analysts are Forex Pros,

Alkermes Regains Full Commercialization Rights to VIVITROL(R) in US  -  Dec 1, 2008
...today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL(R) (naltrexone for extended-release injectable MarketWatch

Alkermes Regains Vivitrol Rights, Biogen Idec Heads for the Burbs ...  -  Dec 2, 2008
Cephalon of Frazer, PA, relinquished its share of the product, an extended-release version of the drug naltrexone marketed under the name Vivitrol. Xconomy,

Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral ...  -  Dec 4, 2008
VIVITROL(R), the company's first commercial product in addiction, is currently approved for the treatment of alcohol dependence in the US and Russia. MarketWatch

Bind Biosciences subleases Alkermes lab space  -  Dec 2, 2008
In an recent unrelated news, Alkermes said that it has regained US commercialization rights to Vivitrol, an injectable medication for the treatment of Boston Globe,

Alkermes Gets Alcohol Drug Rights From Cephalon  -  Dec 2, 2008
...naltrexone for extended release injectable suspension (Vivitrol), while Alkermes will pay Cephalon about $16 million for manufacturing equipment. Xconomy,

Cephalon ends Alkermes pact; Duramed wins FDA OK;  -  Dec 1, 2008
Cephalon has agreed to pay Alkermes $11 million to end their collaboration on Vivitrol for alcohol dependence. Alkermes regains full commercialization FierceBiotech,

Alkermes rises on Risperdal Consta forecast  -  Dec 19, 2008
It also excludes the US rights to Vivitrol, an injectable treatment for alcoholism, and Alkermes' drug candidates, which include an oral treatment for Forbes,

Cephalon drops collaboration with Alkermes for Vivitrol  -  Dec 2, 2008
Alkermes said its partnership with Cephalon on Vivitrol, an injectable treatment for alcoholism, was discontinued. The decision, which is a result of SmartBrief,

Alkermes "neutral," target price reduced  -  Dec 2, 2008
In a research note published this morning, the analysts mention that Alkermes has regained the commercialization responsibility of the Vivitrol product from newratings.com,

Cephalon drops collaboration with Alkermes for Vivitrol  -  Dec 2, 2008
Alkermes said its partnership with Cephalon on Vivitrol, an injectable treatment for alcoholism, was discontinued. The decision, which is a result of SmartBrief,

S&P Picks and Pans: Yahoo, eBay, Ford, Johnson & Johnson, Alkermes  -  Dec 1, 2008
We see modest Vivitrol growth for alcohol dependence and we are wary of costs needed to promote the drug, but we view it as a minor long-term value driver. BusinessWeek

Daily Briefing  -  Dec 2, 2008
Cephalon and Alkermes Inc. end collaboration on alcoholism drug Cephalon Inc. and Alkermes Inc. ended their collaboration on Vivitrol, a drug to treat The News Journal,

Business news in brief  -  Dec 2, 2008
The arrangement gives Alkermes full commercialization rights in the United States for Vivitrol. - AP A Pilgrim's Pride meat-processing plant in Franconia, Philadelphia Inquirer,

Extended-release naltrexone, treatment for alcohol dependence ...  -  Dec 1, 2008
XR-NTX (Vivitrol™) is a once-a-month injectable formulation for AD treatment; its 380 mg dose has been FDA-approved since 2006. EurekAlert (press release),

Market Report -- In Play (ALKS)  -  Dec 1, 2008
Alkermes regains full commercialization rights to VIVITROL in US Co announces that it has regained from Cephalon (CEPH) full commercialization rights to MSN Money

Pre Market Stock News Brief  -  Dec 1, 2008
...(+) ALKS(+15.2%) regains commercial rights to Vivitrol from Cephalon (CEPH), revises guidance up. (+) QI (+24%) reports progress on partner talks, istockAnalyst.com (press release),

US Market Update  -  Dec 1, 2008
In other equity news, Alkermes announced it has cancelled its collaboration agreement with Cephalon and regained rights to Vivitrol. FXstreet.com The Foreign Exchange Market,

纳曲酮引起注射部�?�?良�??应  -  Dec 8, 2008
...�?�中国医�?�报讯日�?,美国食�?�?��?管�?�局（FDA）�?�布信�?�，警告纳曲酮注射用缓释混悬剂（Vivitrol 中国医�?�报,

Alkermes, Inc. F2Q09 (Qtr End 09/30/08) Earnings Call Transcript  -  Nov 18, 2008
We also have the opportunity to grow commercial upside with VIVITROL in our expanding pipeline of proprietary product candidates; David will provide an Seeking Alpha,

Alkermes Announces Second Quarter Fiscal 2009 Results  -  Nov 6, 2008
Manufacturing revenues for the quarter ended September 30, 2008 consisted of $30.7 million for RISPERDAL CONSTA and $2.3 million for VIVITROL(R), Trading Markets (press release),

Alkermes' Corporate Presentation to be Webcast at Lazard Capital ...  -  Nov 11, 2008
...to improve patients' lives, manufactures RISPERDAL(R) CONSTA(R) for schizophrenia and developed and manufactures VIVITROL(R) for alcohol dependence. MarketWatch

Alkermes to Host Conference Call to Discuss Financial Results for ...  -  Oct 31, 2008
...to improve patients' lives, manufactures RISPERDAL(R) CONSTA(R) for schizophrenia and developed and manufactures VIVITROL(R) for alcohol dependence. PharmaLive.com (press release),

The continued uptake of existing brands and the launch of two ...  -  Nov 9, 2008
Companies developing naltrexone depot drugs will experience difficulty distinguishing their products from Vivitrol (naltrexone once-monthly Live-PR.com (Pressemitteilung),

Cephalon Added to S&P 500 Today  -  Nov 14, 2008
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), MarketWatch

Positive Preclinical Data On Novel, Proprietary Molecule, RDC-1036 ...  -  Nov 19, 2008
VIVITROL® is a registered trademark of Cephalon, Inc.; RISPERDAL® CONSTA® is a registered trademark of Janssen-Cilag group of companies. Medical News Today (press release),

SmallCapReview - Small Cap Stocks to Watch - STVI, VISN  -  Nov 17, 2008
...medicines to improve patients' lives, manufactures RISPERDAL CONSTA for schizophrenia and developed and manufactures VIVITROL for alcohol dependence. TransWorldNews (press release),

Cephalon Receives FDA Approval for TREANDA to Treat Patients with ...  -  Oct 31, 2008
TREANDA, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), MarketWatch

Cephalon Reports Another Strong Quarter  -  Oct 28, 2008
PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), MarketWatch

Cephalon Receives FDA Approval for TREANDA to Treat Patients with ...  -  Nov 3, 2008
TREANDA, AMRIX ® (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL ® (naltrexone for extended-release injectable suspension), PR Newswire (press release),

Cephalon and Eurand Announce Notification of Generic Filing for ...  -  21 Oct 2008
AMRIX, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets SYS-CON Media,

Alkermes shifts gears; plans own drug lines  -  Oct 9, 2008
Chizzo said the company’s achievement in bringing the drug Vivitrol to market gave it the confidence to pursue becoming a full-fledged R&D biotech. Mass High Tech,

FDA Approves New Injection Site For RISPERDAL(R) CONSTA(R) For ...  -  Oct 10, 2008
Medisorb is a registered trademark of Alkermes, Inc., VIVITROL is a registered trademark of Cephalon, Inc. and RISPERDAL CONSTA is a registered trademark of Medical News Today (press release),

SmallCapReview - Small Cap Stocks to Watch For Friday  -  Oct 9, 2008
...manufactures RISPERDAL ® CONSTA ® for schizophrenia and developed and manufactures VIVITROL ® for alcohol dependence. Alkermes' robust pipeline includes TransWorldNews (press release),

David Anstice Elected to Alkermes’ Board of Directors  -  Oct 8, 2008
...manufactures RISPERDAL ® CONSTA ® for schizophrenia and developed and manufactures VIVITROL ® for alcohol dependence. Alkermes' robust pipeline includes Business Wire (press release),

Indevus Puts New Acromegaly Treatment Head-to-Head with Novartis ...  -  Sep 30, 2008
For example, Cambridge, MA-based Alkermes (NASDAQ:ALKS) has seen slow sales of Vivitrol, a once-per-month injection based on generic drug naltrexone to Xconomy,

Cephalon Launches National Consumer Awareness Initiative on ...  -  Oct 14, 2008
TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), PR Newswire (press release),

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com